# Prevention of Anthracycline-induced Cardiotoxicity

> **NCT01968200** · PHASE3 · UNKNOWN · sponsor: **European Institute of Oncology** · enrollment: 268 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Enalapril

## Key facts

- **NCT ID:** NCT01968200
- **Lead sponsor:** European Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-12
- **Primary completion:** 2019-12
- **Final completion:** 2023-12
- **Target enrollment:** 268 (ESTIMATED)
- **Last updated:** 2023-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01968200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01968200, "Prevention of Anthracycline-induced Cardiotoxicity". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01968200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*